Laird Norton Wetherby Wealth Management LLC Has $2.21 Million Position in Pfizer Inc. (NYSE:PFE)

Laird Norton Wetherby Wealth Management LLC cut its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 29.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 83,179 shares of the biopharmaceutical company's stock after selling 35,112 shares during the quarter. Laird Norton Wetherby Wealth Management LLC's holdings in Pfizer were worth $2,207,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. PSI Advisors LLC lifted its position in shares of Pfizer by 1.4% during the 4th quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company's stock valued at $738,000 after acquiring an additional 385 shares during the period. Patriot Financial Group Insurance Agency LLC lifted its position in shares of Pfizer by 1.0% during the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company's stock valued at $1,027,000 after acquiring an additional 391 shares during the period. D Orazio & Associates Inc. lifted its position in shares of Pfizer by 5.5% during the 4th quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company's stock valued at $200,000 after acquiring an additional 391 shares during the period. Lipe & Dalton lifted its position in shares of Pfizer by 17.7% during the 4th quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company's stock valued at $71,000 after acquiring an additional 400 shares during the period. Finally, Beam Wealth Advisors Inc. lifted its position in shares of Pfizer by 1.5% during the 4th quarter. Beam Wealth Advisors Inc. now owns 27,444 shares of the biopharmaceutical company's stock valued at $728,000 after acquiring an additional 401 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the firm's stock in a transaction dated Thursday, February 13th. The stock was bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.06% of the company's stock.

Analyst Upgrades and Downgrades

PFE has been the subject of several recent analyst reports. Cantor Fitzgerald initiated coverage on Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective for the company. UBS Group upped their price objective on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Guggenheim restated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. The Goldman Sachs Group restated a "neutral" rating and set a $25.00 price objective (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Finally, Citigroup restated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, four have assigned a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $29.17.

Pfizer Price Performance

Pfizer stock opened at $23.09 on Tuesday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $131.25 billion, a PE ratio of 16.37, a P/E/G ratio of 0.64 and a beta of 0.58. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The stock has a 50-day moving average price of $23.96 and a two-hundred day moving average price of $25.48.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. The company had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business's quarterly revenue was down 7.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.82 earnings per share. Analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be paid a $0.43 dividend. The ex-dividend date is Friday, May 9th. This represents a $1.72 annualized dividend and a dividend yield of 7.45%. Pfizer's payout ratio is 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.